Abnormal Liver Transaminases...To biopsy or not to biopsy?

DR. PHILIP WONG, ASSOCIATE PROFESSOR OF MEDICINE, MCGILL UNIVERSITY


DR. SUSAN GILMOUR, PROFESSOR OF PEDIATRICS, UNIVERSITY OF ALBERTA

Disclosures

► Dr. Gilmour

Clinical trials, site PI Abbvie, Mirum

Biopsy: Completing the picture or just adding to it?



Case Study

20 year old male referred to your GI practice because of elevated liver transaminases on pre-isotretinoin screening

- Labs from family physician:
 - ► AST 105 u/l [6-35 u/l]
 - ► ALT 98 u/l [6-45 u/l]
 - ► ALP 275 u/l [53-128 u/l]
 - ► GGT 50 u/l [7-50 u/l]
 - ► Tbili 18 µmol/l [1.7-18.9 u/l]

Case Study (con't)

20 year old male previously healthy, no oral antibiotic therapy for acne, no colitis symptoms, no family history of liver disease or IBD

Patient is not sure why he is in a GI office, he states he feels well and he HATES needles

Further Investigations?

THE FUTURE OF HEALTHCARE ARE WE HEADED FOR AI OR VIRTUAL DOCTORS?




Further Investigations

- ► ANA 1:80; IgG 18 g/l [7-15 g/l]
- SMA neg; AMA neg; LKM neg
- Cu; ceruloplasmin; ferritin, alpha 1 all normal
- EBV old infection; Hep A, B, C negative and reflect immunization for HBV
- Ultrasound: very mild heterogeneity ; no hepatosplenomegaly; normal portal flow
- Radiology did an ultrasound shear wave: "mild fibrosis score"

Next Steps...

Treat based on biochemistry? Liver biopsy then decide on therapy?

Histology




Case Study (con't)

- Prednisone 50 mg po q daily was started, and then azathioprine 100 mg daily was added
- Transaminases trend down but do not normalize
- When the prednisone was weaned the transaminases increase to more than initial presentation
- Patient very clear that they are adherent with medications (and patient is mildly Cushingoid; 6 TGN levels in therapeutic range)



? Change pharmacotherapy
?Rebiopsy
?MRCP
All of the above
None of the above

MRCP: "attenuated intrahepatic ducts"



Overlap Syndrome: Entity or Evolution


Dilemma

► AIH, PBC, PSC have emerged as distinct clinical entities

- But none of these have known distinct etiological agents, or distinctive pathogenic pathways to definitively define them
- These are all clinical syndromes with clinical, lab, serological, genetic and histological features that can be shared.
- We define by the clustering of the above

AIH with Secondary Features = Overlap Syndromes

Czaja Dig Dis Sci 2013



Overlap Syndrome

AIH has been described in overlap with cholangiopathies:

- AIH and Primary biliary cirrhosis
- AIH and Primary sclerosing cholangitis
- No validated criteria for the diagnosis of AIH/PBC or AIH/PSC
- Literature describes the two entities being diagnosed at the same time, AIH first or PBC/PSC first diagnosed



Frequency of overlap AIH/PBC 7 to 13% of AIH patients (adult)

- Retrospective studies have found that these patients have:
 - ► Higher AST/ALT to PBC alone
 - Higher δ -globulin levels
 - Higher prevalence of other autoimmune disorders
 - ► Efe et al Eur J Gastroenterol Hepatol 2012
 - ► Heurgue et al J Gastroenterol Hepatol 2010

Paris Criteria

Require the presence of 2/3 clinical hallmarks of each disease, AIH and PBC

► AIH

- ► ALT 5 X ULN
- ► IGg 2 X ULN
- ► + SMA
- ► Histology of interface hepatitis

► PBC

- ► ALP 2 X ULN
- ► GGT 2 X ULN
- ► AMA +
- Histology of duct lesions



Frequency of overlap is 6 to 11% of AIH patients

- Less female prevalence vs AlH alone
- More likely to be associated with IBD than AIH alone
- Pediatric study found that 31% of AIH patients had histological evidence of biliary damage
 - Czaja Dig Dis Sci 2013
 - ▶ Gregorio et al Hepatol 2001

Diagnostic Criteria AIH/PSC

- ► No specific criteria
- Clinically these are patients with:
 - ► AIH predominantly
 - Cholestatic labs
 - Absence of AMA
 - Histological and/or radiographic findings of bile duct injury or loss
 - Concurrent IBD (+/-)
 - Non-responsive to conventional corticosteroid therapy

Discussion!

